Zoetis: A compelling investment in animal health.

Zoetis is the world’s largest animal health company and a leading provider of medicines, vaccines, and diagnostic tools for pets and farm animals. Known for its strong portfolio of trusted products, the company combines scientific expertise with a broad business model that covers research, production, and global sales. With a strong position in key areas such as parasite protection, skin conditions, and pain treatment, ongoing innovation, and a pipeline targeting new areas of animal health, Zoetis aims to strengthen its leadership while driving long term growth. The question remains: Does this animal health leader deserve a spot in your portfolio?

This is not a financial advice. I am not a financial advisor and I only do these post in order to do my own analysis and elaborate about my decisions, especially for my copiers and followers. If you consider investing in any of the ideas I present, you should do your own research or contact a professional financial advisor, as all investing comes with a risk of losing money. You are also more than welcome to copy me. 

For full disclosure, I should mention that I do not own any shares in Zoetis at the time of writing this analysis. If you would like to copy or view my portfolio, you can find instructions on how to do so here. If you want to purchase shares or fractional shares of Zoetis, you can do so through eToro. eToro is a highly user-friendly platform that allows you to get started on investing with as little as $50.

The Business

Zoetis was founded in 1952 as part of Pfizer and became an independent company in 2013. Today, it is the world’s leading animal health company, focused on discovering, developing, manufacturing, and selling medicines, vaccines, diagnostics, genetic tests, biodevices, and precision animal health solutions. The company serves both companion animals, such as dogs, cats, and horses, and livestock, such as cattle, swine, poultry, fish, and sheep. This gives Zoetis a diversified business model across species, geographies, and product categories. Its products are used by veterinarians, pet owners, livestock producers, and commercial farming operations around the world. Zoetis operates across major product categories such as parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, diagnostics, and other pharmaceutical products. Companion animals have become the largest part of the business and represent the majority of revenue. This reflects the long-term trend of pet humanization, where pet owners increasingly view animals as family members and are more willing to spend money on advanced care, chronic treatments, diagnostics, and preventive medicine. Livestock remains another important part of the company, as its products help producers prevent disease, improve animal welfare, increase productivity, and support the production of safe and reliable animal protein. This combination gives Zoetis exposure to both consumer-driven pet healthcare and the essential need for animal protein production. A key part of Zoetis’ business model is its broad portfolio. The company has around 300 product lines and several leading franchises, including Simparica, Simparica Trio, Apoquel, Cytopoint, Librela, Solensia, ProHeart, Revolution, and its Vetscan diagnostics platform. Many of these products require repeat use, which creates recurring demand. Pets need ongoing protection against fleas, ticks, heartworm, itching, allergies, infections, and chronic pain, while livestock producers need vaccines, anti-infectives, and parasite control to keep herds and flocks healthy. This creates a business model with durable demand, strong customer retention, and attractive margins. Zoetis also benefits from lifecycle innovation, where existing products are improved through new claims, new formulations, new species, longer duration, or geographic expansion. This allows the company to extend the value of successful products over many years instead of relying only on completely new launches. The company also has a strong commercial model, supported by a large global sales organization and deep relationships with veterinarians and livestock producers. Its sales representatives and veterinary specialists do more than sell products. They provide medical education, technical support, disease management advice, and training on treatment protocols. These relationships give Zoetis valuable insight into customer needs and help the company turn scientific innovation into products that solve real problems in animal care. Zoetis’ competitive moat is built on its scale, trusted brands, broad portfolio, innovation engine, regulatory expertise, customer relationships, and manufacturing capabilities. Its brand trust is one of the company’s most important advantages. Veterinarians and producers are cautious when choosing treatments because animal health outcomes matter, and once a product has proven safe and effective, customers are often reluctant to switch. This creates loyalty around established franchises such as Apoquel, Cytopoint, Simparica Trio, and Librela. The company’s broad portfolio also strengthens its moat because Zoetis can serve customers across the full continuum of care, from predicting and detecting disease to preventing and treating it. This makes the company more valuable to veterinarians and producers than a smaller competitor with only a narrow product offering. Another important advantage is innovation. Zoetis has built one of the strongest R&D engines in animal health, supported by thousands of regulatory approvals, a large pipeline, and capabilities across vaccines, small molecules, monoclonal antibodies, diagnostics, genetics, digital tools, and AI. Its leadership in monoclonal antibodies has helped redefine treatment in areas such as allergic itch and osteoarthritis pain, while its diagnostics platforms create another layer of customer integration. The animal health industry is also highly regulated, which creates barriers to entry. New competitors must prove safety, efficacy, manufacturing quality, and regulatory compliance across different species and markets. Zoetis has decades of experience navigating these requirements, which makes it easier for the company to launch products globally and harder for smaller players to keep up. Scale further strengthens this advantage. Zoetis sells products in more than 100 countries, has a commercial presence in more than 45 markets, operates a large global field force, and runs a broad manufacturing network. This allows the company to spread R&D, regulatory, marketing, and production costs across a large revenue base. It also helps Zoetis launch new products efficiently across regions and respond quickly to customer needs. Manufacturing is another part of the moat, especially in complex products such as vaccines and biologics. These products are difficult to develop and manufacture consistently at scale, which limits direct competition. Combined with patent protection, regulatory barriers, customer loyalty, and strong execution, this gives Zoetis a durable competitive position. Overall, Zoetis has built a powerful animal health platform with trusted brands, recurring demand, global scale, and a long track record of innovation. Its moat is not based on one single factor, but on the combination of scientific expertise, customer relationships, broad product coverage, manufacturing strength, and the ability to repeatedly turn unmet medical needs into successful commercial products.

Management

Kristin Peck serves as the CEO of Zoetis, a role she assumed in 2020 after previously holding several senior leadership positions within the company. She brings extensive experience in animal health, business development, innovation, strategy, and finance, and she played an important role in Zoetis’ creation as an independent company. Her appointment reflected Zoetis’ focus on strengthening its position as the global leader in animal health while continuing to expand into faster growing areas such as companion animal therapeutics, diagnostics, precision animal health, and biologics. Before becoming CEO, Kristin Peck held senior roles at Zoetis, including leadership positions in strategy, business development, and U.S. operations. She was also closely involved in the company’s 2013 IPO, which separated Zoetis from Pfizer and created the world’s largest standalone animal health company. Prior to joining Zoetis, Kristin Peck was Executive Vice President of Worldwide Business Development and Innovation at Pfizer, where she helped evaluate strategic alternatives for Pfizer’s Animal Health and Nutrition businesses, ultimately contributing to the decision to spin off Zoetis. Earlier in her career, Kristin Peck worked at The Boston Consulting Group and held roles in private equity and real estate finance at Prudential Realty Group, The O’Connor Group, and J.P. Morgan. She holds a bachelor’s degree from Georgetown University and an MBA from Columbia Business School. Kristin Peck also serves on several boards, including BlackRock, Columbia Business School, Mayo Clinic, and Catalyst, which reflects her broader experience across finance, healthcare, leadership, and organizational development. Since becoming CEO, Kristin Peck has led Zoetis through a period of strong innovation and continued leadership in animal health. Under her leadership, the company has expanded its portfolio in areas such as dermatology, parasiticides, pain management, diagnostics, and monoclonal antibodies. Zoetis has also continued to build one of the strongest pipelines in animal health, supported by its broad R&D capabilities, global manufacturing network, and deep relationships with veterinarians and livestock producers. Her leadership has emphasized the importance of turning science into practical solutions that address unmet medical needs for animals while creating long-term value for customers and shareholders. Kristin Peck has also been recognized externally for her leadership. She was named to TIME100 Health in 2025, included on CNBC’s Changemakers list in 2024, named one of Barron’s Top CEOs in 2022, and recognized by Fortune as a Businessperson of the Year in 2020. She also received the Feather in Her Cap Award for her contributions to the animal health industry and her mentorship of women leaders. Beyond commercial performance, Kristin Peck has emphasized the importance of culture, agility, innovation, and purpose. Zoetis has reported strong employee engagement, and the company continues to position itself as an important partner to veterinarians, pet owners, and livestock producers around the world. Given her deep knowledge of Zoetis, her role in shaping the company’s independence, her experience in strategy and innovation, and her track record of execution, Kristin Peck appears well suited to continue leading Zoetis through its next phase of growth.

The Numbers

The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year. Zoetis has consistently delivered very high ROIC, with returns ranging from roughly 18% to 24% over the past decade. This level of consistency is rare and it highlights the strength of the company’s operating model. The fact that ROIC has not only remained high but has also reached new highs in the past two years suggests that the business is not only durable but potentially improving. Several structural characteristics explain why Zoetis has been able to generate such high returns on capital. First, the company operates in the animal health industry, which has attractive economics compared to human pharmaceuticals. Development cycles are shorter, success rates are higher, and commercialization is more targeted. This means Zoetis can bring products to market faster and at lower cost, which improves ROIC. Management has explicitly highlighted this as a structural advantage, noting that the combination of faster development, higher success rates, and focused commercialization supports strong margins and high returns. Second, Zoetis benefits from a highly diversified and recurring revenue model. A large portion of its revenue comes from products such as parasiticides, dermatology treatments, vaccines, and pain management therapies that require ongoing use. Pets need continuous treatment, and livestock producers need consistent disease prevention. This creates repeat sales without requiring significant incremental capital investment. When a company can grow revenue without proportionally increasing its capital base, ROIC naturally improves. Third, the strength of Zoetis’ portfolio plays an important role. The company has built leading franchises such as Apoquel, Cytopoint, Simparica Trio, and Librela, which are widely trusted by veterinarians and pet owners. These products often become part of standard treatment protocols, creating strong customer retention and pricing power. Once a veterinarian adopts a treatment, switching is less likely, which allows Zoetis to generate stable and predictable returns on its invested capital. Fourth, Zoetis benefits from scale and disciplined capital allocation. Management has emphasized that the company invests heavily in R&D but does so with focus, targeting areas where it can lead and create lasting impact. Importantly, R&D has remained relatively stable as a percentage of revenue, even as absolute investment has increased. This means Zoetis is growing its innovation engine without losing efficiency. The company also spreads its R&D, manufacturing, and commercial infrastructure across a large global revenue base, which improves capital efficiency and supports high returns. Fifth, the company’s direct commercial model strengthens its economics. Zoetis maintains close relationships with veterinarians and livestock producers through its large field force, providing not just products but also education, technical support, and insights. This creates switching costs and improves customer retention, allowing Zoetis to generate more revenue from its existing customer base without needing large incremental investments. Looking at the recent increase in ROIC, from around 20% to nearly 24%, there are a few likely drivers. One is mix. The companion animal segment, which has higher margins and better economics, continues to grow as a share of total revenue. Another is innovation. Newer products, particularly in dermatology and pain management, tend to have strong pricing and high margins. Management has also pointed to strong execution, disciplined capital allocation, and a portfolio designed for durability as key reasons for improving returns. The key question is whether these elevated levels are sustainable. There are good reasons to believe that ROIC can remain high, although continued expansion from already high levels may be more difficult. The structural drivers are still in place. Zoetis continues to invest in innovation, expects a steady cadence of approvals, and operates in a resilient market supported by long-term trends such as pet humanization and growing demand for animal protein. Its ability to turn innovation into commercial products efficiently is a core strength, and management has described this as a repeatable model rather than a one-time outcome. At the same time, there are factors that could limit further expansion in ROIC. Continued investment in R&D, manufacturing capacity, and new technologies such as diagnostics, AI, and precision animal health will increase the capital base. Expansion into new markets or new therapeutic areas may also take time to reach full profitability. In addition, as the company grows larger, maintaining incremental improvements in already high returns becomes more challenging. Overall, Zoetis has demonstrated an exceptional ability to generate high and stable ROIC over time. This is driven by a combination of strong margins, recurring revenue, efficient R&D, scale advantages, and disciplined capital allocation. While ROIC may fluctuate modestly and may not continue rising at the same pace, the underlying business model suggests that Zoetis should be able to sustain high returns for many years.

The next numbers are the book value + dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to see the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders – like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we’re essentially looking at how much value is being built for shareholders year after year. Zoetis has grown its equity nicely for many years, especially from 2016 to 2021, where growth was strong and consistent. This reflects that the company was earning good money and keeping part of those earnings in the business, which helped build value over time. However, in the past few years, equity has stopped growing and has even declined, with a noticeable drop in 2025. This might look concerning at first, but it does not necessarily mean the business is getting weaker. One of the main reasons is that Zoetis is a very profitable company that does not need a lot of capital to grow. When a business earns more money than it needs to reinvest, the extra cash is often used in other ways. Zoetis has used part of this excess cash to buy back its own shares, and when a company repurchases shares, it reduces the equity on the balance sheet. This means equity can go down even when the company is performing well. Another reason is that Zoetis has been adjusting its business portfolio, including selling parts of the business that are less attractive. When a company sells a business unit, the total value on the balance sheet can decline, which also shows up as lower equity. This is more about reshaping the company than weakening it. In addition, Zoetis operates globally, so currency movements can cause some fluctuations from year to year. The large decline in 2025 is therefore most likely a combination of share repurchases, portfolio changes, and normal accounting movements rather than a sign of weaker performance. In fact, when you look at this together with the company’s high and rising ROIC, it suggests that Zoetis is becoming more efficient. It is able to generate strong profits without needing to keep adding more capital. Looking ahead, equity for Zoetis will likely continue to move up and down instead of growing in a straight line. This is normal for a business that generates strong cash flows and actively returns capital while optimizing its portfolio. The important thing is that the company continues to create value through strong earnings and high returns rather than simply increasing equity every year.

Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins offer a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share. Zoetis has historically generated strong free cash flow and high free cash flow margins, often above 20%. This shows that a large share of the company’s revenue turns into real cash, which is a key sign of a high-quality business. One of the main reasons for this is Zoetis’ strong profitability. The company sells products that are essential for animal health and often used repeatedly, such as treatments for parasites, skin conditions, and chronic pain. These products tend to have strong pricing and stable demand, which means that a large part of revenue becomes profit and eventually cash. Another important reason is that Zoetis does not need to spend heavily to keep the business running and growing. While it continues to invest in research, manufacturing, and new products, these investments are relatively small compared to the cash it generates. Management has highlighted that it can develop and launch new products more efficiently than many human healthcare companies, which supports strong cash generation. The company also benefits from recurring demand. Pets need ongoing treatment, and livestock producers need continuous disease prevention, which creates stable and predictable cash flows year after year. The changes we see in certain years are usually due to timing. For example, some years include higher spending on new facilities, acquisitions, or building up inventory, which can reduce free cash flow temporarily. This helps explain why free cash flow was lower in 2022 but then increased again in the following years. The important point is that the overall level remains high over time. Looking ahead, Zoetis is likely to continue generating strong free cash flow. The business still benefits from high margins, recurring revenue, and efficient operations, and management has stated that the company has the ability to continue improving margins over time while still investing for growth. While the numbers may move slightly from year to year, the overall level is expected to remain strong. Zoetis uses its free cash flow in a clear and disciplined way. First, it reinvests in the business, especially in research and development, new products, and expanding its capabilities. Second, it looks for acquisitions that can strengthen its position, such as the recent genomics deal. Finally, the company returns excess cash to shareholders through both share buybacks and dividends, which have been a consistent part of its strategy and were particularly high in 2025. Overall, Zoetis’ strong free cash flow reflects the quality of its business model and is likely to remain a key strength going forward. The free cash flow yield suggests that while the shares are not cheap, they are trading at their most attractive valuation in more than a decade. However, we will revisit valuation later in the analysis.

Debt

Another important aspect to consider is the level of debt. It is crucial to determine whether a business has manageable debt that can be repaid within a three-year period. This is calculated by dividing total long-term debt by earnings. After analyzing Zoetis’ financials, I found that the company has 3,4 years' worth of earnings in debt, which is slightly above the three-year threshold. This is not a major concern, but it is worth understanding why it is a bit higher than usual. One of the main reasons is that Zoetis has actively returned capital to shareholders, including large share buybacks. In 2025, the company even used a debt transaction to support a significant buyback program, which temporarily increased its debt level. Management has emphasized that maintaining a strong balance sheet remains a priority, and the company still has flexibility to invest in the business and pursue acquisitions. Given Zoetis’ strong and stable cash flow, the current debt level appears manageable, but it is something worth monitoring to ensure it trends back toward more conservative levels over time.

Support the Blog

I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!

Risks

Competition is a risk for Zoetis because the company operates in a highly competitive industry where several strong players are constantly trying to gain market share across medicines, vaccines, and diagnostics. Even though Zoetis is the largest animal health company globally, it competes directly with well-established companies such as Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health, and IDEXX Laboratories, as well as a large number of smaller and more specialized players. These competitors often have significant financial and research resources, which allows them to invest heavily in developing new products, marketing them aggressively, and building strong relationships with veterinarians and livestock producers. As a result, Zoetis must continuously innovate and maintain strong execution to defend its leading position. One of the main ways competition affects Zoetis is through new product launches. Many competitors are developing treatments in the same areas where Zoetis is strong, such as dermatology, parasiticides, and pain management. When new products are launched, competitors often use aggressive pricing and promotional strategies to gain a foothold in veterinary clinics. Management has highlighted that during launch periods, competitors tend to price products lower than they can sustain long term and invest heavily in promotions to secure shelf space and build awareness. This can temporarily put pressure on Zoetis’ sales and margins, especially in key categories like dermatology where competition has increased significantly in recent years. Another important factor is pricing pressure. As competition increases, Zoetis may be forced to lower prices or increase promotional spending to remain competitive. This is particularly relevant in categories where multiple similar products exist or where patents have expired. While the animal health market has historically been less exposed to large-scale generic competition than human pharmaceuticals, lower-cost alternatives are becoming more common. In price-sensitive markets, these alternatives can lead to reduced pricing power and slower growth if Zoetis cannot clearly differentiate its products. Industry consolidation also increases competitive pressure. Larger competitors can expand their product portfolios through acquisitions and offer bundled solutions to customers. This makes them more attractive partners for veterinarians and livestock producers, who may prefer to source multiple products from a single supplier. At the same time, consolidation among veterinary clinics, such as large corporate groups, increases the bargaining power of customers. Larger clinic groups can negotiate better pricing and terms, which can put additional pressure on margins across the industry. Competition is also a risk because innovation is critical in animal health. Zoetis invests heavily in research and development, but competitors are doing the same. If a competitor launches a more effective, safer, or more convenient product, it can quickly gain market share. This is especially important in fast-growing areas such as dermatology and biologics, where new treatments can change standard care. Management has noted that 2026 could bring particularly strong competitive pressure in some core therapeutic areas due to multiple upcoming launches, which may lead to increased promotional activity and pricing competition. Finally, competition can influence how quickly Zoetis can grow in new markets and categories. Start-ups and niche players often focus on specific technologies or segments, which can allow them to move quickly and introduce innovative solutions. At the same time, large pharmaceutical companies with animal health divisions can leverage their broader research capabilities and global reach. This combination of large, well-funded competitors and smaller, focused innovators creates a dynamic and competitive environment.

Regulations are a risk for Zoetis because the company operates in a highly regulated industry where every product must meet strict requirements before it can be sold and continue to meet those requirements after it is on the market. Zoetis develops medicines, vaccines, and diagnostics that are used in animals, which means it must comply with rules set by multiple authorities such as the FDA, USDA, EMA, and similar agencies around the world. These regulators require proof that products are safe, effective, and consistently manufactured, and they regularly monitor products even after approval. This creates a complex environment where Zoetis must constantly meet high standards across many different countries. One of the main ways regulations create risk is through product approvals. Before Zoetis can sell a new product, it must go through a lengthy approval process in each market. These processes can take time and are not always predictable. Delays can slow down product launches and push back expected revenue. This is particularly important for Zoetis because a large part of its growth depends on bringing new products to market. If approvals are delayed or denied, it can affect both growth and profitability. Another important factor is that regulations do not stop after a product is approved. Zoetis’ products are continuously monitored, and regulators can require changes if new safety concerns arise. In some cases, this can lead to updated warnings, restricted use, or even products being removed from the market. Recent scrutiny around products such as Librela and Solensia, including ongoing safety reviews and legal cases, shows how regulatory attention can impact both sales and reputation. Even if the outcome is manageable, the process can create uncertainty and negative publicity. Regulations also affect how Zoetis manufactures its products. The company operates a global manufacturing network, and all facilities must meet strict quality standards. If issues are identified, regulators can require production changes or temporarily halt manufacturing. This can disrupt supply and increase costs. Zoetis also relies on third-party manufacturers in some cases, which means it is exposed to risks outside its direct control. In addition, Zoetis operates globally, which adds another layer of complexity. Each country has its own rules and approval processes, and these can change over time. New regulations, stricter standards, or changing policies can increase costs or limit market access. Legal risks are closely tied to regulation. Zoetis can face lawsuits related to product safety, labeling, or marketing. These cases can be costly, take time to resolve, and affect the company’s reputation. Even if the company ultimately prevails, legal proceedings can distract management and create uncertainty for investors. Finally, regulations can influence how Zoetis markets its products. The company is limited to promoting only approved uses, and any changes in labeling or claims must be approved by regulators. This can make it harder to respond quickly to competitors or to highlight certain product benefits, especially in fast-moving markets.

Macroeconomic factors are a risk for Zoetis because animal health spending, while resilient, is not completely immune to pressure on household budgets. Pet owners usually continue to spend on urgent and emergency care, but they may delay routine visits, wellness checks, and non-urgent treatments when inflation, higher living costs, student loans, or weaker consumer confidence reduce their financial flexibility. This matters because many Zoetis products are prescribed or started during veterinary visits. If fewer pet owners visit the clinic for routine or therapeutic care, it can reduce new patient starts and slow growth in products used for dermatology, pain management, diagnostics, vaccines, and preventive care. One of the clearest examples is the pressure Zoetis has seen among Gen Z and Millennial pet owners. Management has noted that these groups are facing tighter household budgets, including pressure from student loans and the cost of buying a home. At the same time, veterinary clinics have raised prices significantly in recent years, and in some cases those price increases have been above general inflation. This has made some pet owners more careful about when they visit the vet and what treatments they accept. The result is not necessarily that people care less about their pets, but that they become more selective. They may still pay for emergency care, but postpone wellness visits or delay treatment for conditions that do not feel immediately urgent. This is important for Zoetis because routine veterinary visits help drive demand for many of its products. A dog with allergic itch, for example, may need treatment, but the pet owner first needs to visit the clinic, receive a diagnosis, and start therapy. If fewer pet owners visit the clinic, there are fewer opportunities for veterinarians to start new treatments. Management has specifically pointed to slower periodic visits as a headwind to new patient starts, especially in therapeutic areas such as dermatology. This can affect volumes even if the long-term need for the product remains intact. Macroeconomic pressure can also increase price sensitivity. If pet owners face higher living costs, they may become more willing to ask for cheaper alternatives, delay refills, or reduce the frequency of treatment. This can affect Zoetis because many of its leading companion animal products are premium treatments. While strong brands and clinical trust provide protection, they do not completely remove the risk that some customers choose lower-cost options during tougher economic periods. The livestock side of Zoetis is also exposed to macroeconomic factors, although in a different way. Livestock producers are affected by feed costs, animal protein prices, interest rates, trade restrictions, disease outbreaks, and general economic conditions. If producers are under financial pressure, they may reduce spending, delay purchases, or look for lower-cost products. Since Zoetis sells vaccines, medicines, diagnostics, and other solutions to livestock producers, weaker economics in farming can affect demand in certain categories or regions.

Reasons to invest

The powerful human-animal bond is a compelling reason to invest in Zoetis because it creates strong and lasting demand for animal healthcare that is less dependent on economic cycles than many other industries. Over the past decades, pets have increasingly become part of the family, and this shift has fundamentally changed how people think about spending on animal health. Pet owners today are more emotionally connected to their animals and are therefore more willing to invest in their well-being, whether that is preventive care, diagnostics, or advanced treatments. This creates a durable demand base for companies like Zoetis that provide essential healthcare products for animals. One of the most important drivers behind this trend is the changing profile of pet owners. Millennials and Gen Z now make up a large share of pet owners, and many of them view themselves as pet parents rather than simply owners. These generations are often delaying or forgoing children, and pets play a more central role in their lives. As a result, they are more willing to spend on high-quality care, even when budgets are under pressure. Management has noted that even in a softer consumer environment, pet owners continue to prioritize spending on animal health, particularly when their pets are sick or require urgent care. This highlights how emotionally driven demand can support resilience in the business. Another key factor is the increasing medicalization of pets. As the human-animal bond strengthens, pet owners expect the same level of care for their animals as they do for themselves. This has led to greater use of diagnostics, more frequent veterinary visits, and increased adoption of advanced treatments. Zoetis benefits directly from this trend because it operates in many of the fastest-growing therapeutic areas, including dermatology, pain management, and chronic disease treatment. As expectations for care rise, demand for these types of products continues to grow. The aging pet population further strengthens this trend. Pets are living longer than ever before, with lifespans increasing significantly over the past few decades. At the same time, many pets adopted during the pandemic are now entering middle age. As pets age, they are more likely to develop chronic conditions such as osteoarthritis, allergies, kidney disease, and other long-term health issues. These conditions often require ongoing treatment, which increases both the frequency and duration of care. This creates a steady and growing demand for Zoetis’ products, particularly in areas that require continuous treatment over time. This combination of stronger emotional attachment, higher expectations for care, and longer lifespans leads to higher spending per pet. Importantly, this spending is not limited to emergency care. While pet owners may sometimes delay routine visits during periods of economic pressure, they ultimately seek treatment when their pets need it. Management has highlighted that veterinary clinic revenue continues to grow, supported by both higher prices and continued demand for care. This indicates that the underlying willingness to spend remains intact, even if the timing of visits changes. Another important aspect is that the human-animal bond creates recurring demand. As more pets receive regular veterinary care, demand for preventive treatments, diagnostics, and chronic therapies increases. This leads to more predictable revenue streams and higher lifetime value per animal. For Zoetis, this is particularly valuable because many of its products are used repeatedly over long periods, creating a compounding effect on revenue growth.

Structural trends in the livestock segment are a compelling reason to invest in Zoetis because they provide a long-term, global, and relatively predictable source of growth that is driven by fundamental needs rather than short-term cycles. At its core, the livestock business is tied to food production, and demand for animal protein continues to increase as the global population grows and more people enter the middle class. As incomes rise, diets tend to shift toward higher protein consumption, which directly increases demand for meat, dairy, and fish. This creates a steady need for solutions that improve animal health, productivity, and efficiency, which is exactly where Zoetis operates. One of the most important drivers is population growth and rising living standards. The global population is expected to approach 10 billion by 2050, and at the same time, millions of people are moving into the middle class, particularly in emerging markets. As this happens, protein consumption increases significantly. This is not a short-term trend but a long-term structural shift that has been in place for decades and is expected to continue. Zoetis benefits from this because healthier animals are essential for producing safe, reliable, and affordable protein at scale. Another important trend is the shift in how livestock is managed. The industry is increasingly moving from treating diseases after they occur to preventing them in the first place. Producers are investing more in vaccines, diagnostics, and genetic solutions to keep animals healthy and improve productivity. This shift toward prevention creates more stable and recurring demand for Zoetis’ products, especially in areas such as vaccines and biologics. Management has highlighted that these categories are growing faster than the overall livestock market, which positions Zoetis well for continued growth. The mix of protein consumption is also evolving in a way that benefits Zoetis. The fastest-growing sources of protein globally are poultry, fish, and pork, and Zoetis has strong positions in these areas. Aquaculture, in particular, is one of the fastest-growing segments, as fish is an efficient and increasingly important source of protein. Zoetis’ leadership in aquaculture and its growing presence in poultry and swine markets provide exposure to these high-growth areas, which helps support overall growth in the livestock segment. In addition, there is a growing focus on sustainability and efficiency in food production. Producers are under pressure to reduce environmental impact while increasing output, which makes animal health even more important. Healthier animals require fewer resources, produce more output, and are less likely to spread disease. Zoetis’ products, including vaccines and genetic solutions, help producers achieve these goals, which strengthens the company’s role as a key partner in the global food supply chain. Recent performance also supports these structural trends. Zoetis has delivered strong growth in its livestock segment in recent years, outperforming the historical growth rate of the industry. Management expects this momentum to continue, with mid-single-digit growth supported by both volume and pricing. The company has also sharpened its focus on higher-value areas after divesting its medicated feed additives business, allowing it to concentrate on vaccines, biologics, and genetics, which have better growth and margin profiles. Another factor supporting the outlook is changing consumer behavior, even in developed markets. There is an increasing focus on health, nutrition, and protein intake, which is supporting demand for animal-based protein. Trends such as the rise of GLP-1 drugs and a broader focus on maintaining muscle mass are also contributing to higher protein consumption. This adds an additional layer of demand beyond traditional drivers such as population growth and income expansion.

The companion animal portfolio and pipeline are compelling reasons to invest in Zoetis because the company already has leadership positions in several of the most important categories in pet healthcare while also building the next generation of growth drivers. This is not just about benefiting from higher pet spending. It is about having the right products in the right categories, supported by strong brands, high customer satisfaction, lifecycle innovation, and a pipeline that targets some of the largest unmet needs in veterinary medicine. One of the clearest examples is the Simparica franchise. Simparica Trio has become the number one selling canine parasiticide globally and passed $1 billion in U.S. revenue in 2025. The product benefits from the continued shift toward triple combination protection, where one treatment covers fleas, ticks, heartworm, and intestinal parasites. Management has noted that triple combinations have grown from roughly 25% to 30% of the U.S. clinic patient base a few years ago to around 50% today, while puppies are already closer to two-thirds. This suggests the category still has room to expand, and Zoetis is well positioned because Trio has a strong first-mover advantage, high satisfaction levels, and a leading position with new puppies. Dermatology is another major strength. Zoetis has built a large franchise through Apoquel, Apoquel Chewable, and Cytopoint, with the key dermatology portfolio generating around $1.7 billion in revenue in 2025. The strength of this franchise comes from offering veterinarians different treatment options depending on the patient and owner preference. Apoquel provides an established oral option, Apoquel Chewable improves convenience and compliance, and Cytopoint offers an injectable alternative that many veterinarians and pet owners value. This portfolio approach makes Zoetis harder to compete with because it does not rely on just one product format. Even with new competitors entering dermatology, Zoetis benefits from more than a decade of experience, strong brand loyalty, and very high satisfaction levels for safety and efficacy. Osteoarthritis pain is another important opportunity, although it has recently been more challenging. Librela declined in 2025, but Zoetis still believes the long-term opportunity remains significant because many dogs with osteoarthritis pain are either untreated or treated with older options. Solensia has continued to grow in cats, and the approvals of Lenivia for dogs and Portela for cats in Europe and Canada give Zoetis a broader portfolio in pain management. These long-acting therapies could be important because they provide several months of relief with one injection, which may make treatment more convenient for pet owners and improve how long pets stay on therapy. Beyond the current portfolio, the pipeline is a major part of the investment case. Zoetis is developing products in areas such as chronic kidney disease, oncology, cardiology, anxiety, obesity, and metabolic disease. These are not small niche opportunities. Management has highlighted chronic kidney disease as one of the largest unmet needs in animal health, with a potential market of $3 billion to $4 billion. Oncology and cardiology also represent large future opportunities, especially because current treatment options are often limited, difficult to access, or mainly available through specialist clinics. What makes the pipeline especially interesting is that Zoetis is not starting from scratch. Many of these opportunities build on capabilities the company already has, including monoclonal antibodies, diagnostics, biomarkers, and experience turning new categories into commercial markets. This is important because Zoetis has already shown that it can create and scale categories in animal health, as it did in dermatology and osteoarthritis pain. The company also continues to support growth through geographic expansion and lifecycle innovation. In 2025, Zoetis delivered more than 185 geographic expansions and lifecycle innovations, which means the company is constantly extending existing products into new markets, new formulations, new claims, or new patient groups. This creates a steadier growth profile than relying only on major new product launches.

Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.

1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters

Special Price: $269/year (normally $299) + 7-day free trial (for new users only)

Try Premium Free for 7 Days → HERE

(Explore everything — cancel anytime during the trial and pay $0.)

2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.

Special Price: $449/year (normally $499)

Get Alpha Picks → HERE

(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).

3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.

Special Price: $639/year (normally $798)

Get the Bundle → HERE

(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)

Valuation

Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.

The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. I chose to use an EPS of 6,02, which is from the year 2025. I have selected a projected future EPS growth rate of 9%. Finbox expects EPS to grow by 8,5% in the next five years. Additionally, I have selected a projected future P/E ratio of 18, which is double the growth rate. This decision is based on Zoetis' historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be $63,41. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy Zoetis at a price of $31,70 (or lower, obviously) if we use the Margin of Safety price.

The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 2.904, and capital expenditures were 621. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 435 in our calculations. The tax provision was 687. We have 440,7 outstanding shares. Hence, the calculation will be as follows: (2.904 – 435 + 687) / 440,7 x 10 = $71,61 in Ten Cap price.

The final calculation is referred to as the Payback Time price. It is a calculation based on the free cash flow per share. With Zoetis' free cash flow per share at $5,18 and a growth rate of 9%, if you want to recoup your investment in 8 years, the Payback Time price is $62,27.

Conclusion

I believe that Zoetis is an intriguing company with good management. It has a strong moat built on brand trust, intellectual property, and innovation leadership, supported by its scale, trusted brands, broad portfolio, innovation engine, regulatory expertise, customer relationships, and manufacturing capabilities. Zoetis has consistently achieved a high ROIC, a trend that is expected to continue, and it has also delivered strong free cash flow with high margins, which is likely to persist. Competition is a risk for Zoetis because strong competitors with significant resources continue to launch new products and use aggressive pricing and promotions to gain market share, which can pressure both growth and margins, while increasing innovation, generics, and industry consolidation make it more difficult to maintain pricing power and defend its leading position. Regulations are also a risk because strict approval processes, ongoing monitoring, and evolving rules can delay product launches, increase costs, or lead to restrictions or withdrawals of key products, while regulatory scrutiny and legal risks can create uncertainty and affect both sales and reputation. Macroeconomic factors present another risk, as tighter household budgets can lead pet owners to delay routine veterinary visits and non urgent treatments, reducing new patient starts and slowing demand, while economic pressure can also increase price sensitivity among both pet owners and livestock producers. The powerful human animal bond is a reason to invest in Zoetis because it drives strong and recurring demand for pet healthcare, as owners continue to spend on prevention, diagnostics, and treatments even during weaker economic periods, and this trend, combined with aging pets and increasing use of advanced care, supports durable growth and higher lifetime value per animal. Structural trends in the livestock segment also support the investment case, as rising global protein demand driven by population growth and increasing incomes creates a steady need for solutions that improve animal health and productivity, while the shift toward prevention and exposure to fast growing areas like poultry and aquaculture provide durable and predictable long term growth. The companion animal portfolio and pipeline further strengthen the case, as Zoetis combines leading positions in large and growing categories with strong brands and high customer satisfaction, while its pipeline targets major unmet needs such as kidney disease and cancer and provides a clear path for future growth. Overall, there are many things to like about Zoetis, and buying shares at $100, which represents a 30% discount to the intrinsic value based on the Ten Cap approach, could be an attractive long term investment.

My personal goal with investing is financial freedom. It also means that to obtain that, I do different things to build my wealth. If you have some extra hours to spare each month, you can turn a few hours a week into a substantial amount of money in a few years. If you are interested to know how I do it, you can read this post.

I hope you enjoyed my analysis! While I can’t post about every company I analyze, you can stay updated on my trades by following me on Twitter. I share real-time updates whenever I buy or sell, so if you’re making your own investment decisions, be sure to follow along!

Some of the greatest investors in the world believe in karma, and to receive, you will have to give (Warren Buffett and Mohnish Pabrai are great examples). If you appreciated my analysis and want to get some good karma, I would kindly ask you to donate a bit to Soi Dog. They rescue street dogs in Thailand by giving them food, medicine and vet care. If you have a little to spare, please donate here. Even a little will make a huge difference to save these wonderful animals. Thank you.